#ASH25: Our collaborator María-Victoria Mateos will share results of a phase 3 study of teclistamab plus daratumumab for relapsed refractory #multiplemyeloma. #mmsm @mskcancercenter.bsky.social @ash.hematology.org @szusmani.bsky.social TODAY | 8:45 a.m. EST Learn more: bit.ly/3MN6MKr

Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma. 🗓️ Thursday, September 18 | 4:40 p.m. EDT @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

Coming up at #IMS25: Join MSK's Myeloma Service Chief @szusmani.bsky.social to learn about current challenges in #multiplemyeloma relapse & future research needed to overcome them. #mmsm 🗓️ Friday, September 19 | 9:40 a.m. EDT @mskcancercenter.bsky.social @myeloma-society.bsky.social

At #IMS25, Dr. Francesco Maura will present new research on the genomics that define neoplastic transformation in #multiplemyeloma precursor conditions. #mmsm 🗓️ Saturday, September 20 | 9:20 a.m. EDT @mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social

MSK is headed to Toronto for #IMS25! Stay tuned for posters and presentations that are advancing #multiplemyeloma research and treatments. #mmsm @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

MSK experts have arrived at #IMS25! Join Dr. Francesco Maura to learn about genomic drivers of resistance to anti-BCMA immunotherapies in #multiplemyeloma. #mmsm 🗓️ Wednesday, September 17 | 11:10 a.m. EDT @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

At #IMS25, Dr. Carlyn Tan will share new data on early mortality associated with real-world bispecific antibody therapy for relapsed/refractory #multiplemyeloma. 🗓️ Wednesday, September 17 | 12:14 p.m. EDT @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

Sign up to read exclusive expert insights on key abstracts to watch at #IMS25! @szusmani.bsky.social @mskcancercenter.bsky.social @myeloma-society.bsky.social #mmsm www.onclive.com/view/experts...

Join Dr. @szusmani.bsky.social as he presents research on "Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed #MM (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study" at #ASCO25. @ascocancer.bsky.social

"The phase 3 CEPHEUS trial previously demonstrated improved efficacy outcomes with DVRd vs VRd in patients with TIE or transplant-differed NDMM," shares myeloma specialist @szusmani.bsky.social during his session at #ASCO25. @ascocancer.bsky.social

D-VRd Retains Its Role as a Standard of Care for Transplant-Ineligible Multiple Myeloma @ascocancer.bsky.social @mskcancercenter.bsky.social @szusmani.bsky.social #ASCO25 #mmsm www.onclive.com/view/d-vrd-r...

Congrats to Mark G. Kris, Kenneth Offit, David G. Pfister, and @szusmani.bsky.social on being inducted into the 13th Giants of Cancer Care® class by @onclive.bsky.social! This award honors leading physicians who are advancing #cancerresearch. @mskcancercenter.bsky.social Learn more: bit.ly/42Ox58M

❤️ Thank you, Dr. Usmani for continuing to support #MyelomaICE!

Dear all, putting in a plug for the International Myeloma Foundation Iceland Cycling Expedition 2025 below. Thanks for your generosity last year, many of you contributed to its success. Every donation and any amount counts. @imfmyeloma.bsky.social fundraise.myeloma.org/fundraiser/5...

1/ 🚨New research alert! 🚨Our study in Blood Cancer shows that high WEE1 expression is an independent predictor of poor survival in multiple myeloma, with @joedeasy.bsky.social, @malinhultcrantz.bsky.social, @szusmani.bsky.social, and the rest of the @mskcancercenter.bsky.social team! 🧵👇#MyelomaSky

NEW in @natmedicine.bsky.social: Results from a phase 3 clinical trial led by MSK's #myeloma specialist & cellular therapist @szusmani.bsky.social. Learn more: www.nature.com/articles/s41...

Quadruplets induction regimens are the established standards of care now in newly diagnosed MM, just out 🎉👇🏽 #MyelomaSky @mskcancercenter.bsky.social @imfmyeloma.bsky.social @themmrf.bsky.social @healthtreeorg.bsky.social www.nature.com/articles/s41...

Thanks to @szusmani.bsky.social for donating 🙌🏾🙌🏾🙌🏾🥳🥳🥳 to support multiple myeloma cancer research @ give.themmrf.org/fundraiser/5...

This is your last chance to see incredible research at the #ASH24 poster session today! Don't miss posters by Drs. Gunjan Shah, Carlyn Rose Tan, & Pallawi Torka. @mskcancercenter.bsky.social @szusmani.bsky.social 6-8 p.m. PST https://buff.ly/3ZLbSey https://buff.ly/3OOjjeG https://buff.ly/3Vum0Wv

Congratulations to MSK's Dr. Urvi Shah for being awarded the @ash-hematology.bsky.social David M. Goldenberg Clinical Research Training Institute Award for her work on research that shows that a high-fiber, plant-based dietary intervention may delay progression #MGUS/#SMM to #MM. #ASH24 #ASHKudos

Dr. @szusmani.bsky.social presents on “Working with Data Hub Data and Network PIs to Develop Evidence that Changes Practice in Multiple Myeloma: The COSMIC Study as Proof of Concept” that is part of the ASH Research Collaborative Multiple Myeloma Network at @ash-hematology.bsky.social. #ASH24

Please join us now #ASH24 #MyelomaSky ASH RESEARCH COLLABORATIVE MULTIPLE MYELOMA NETWORK: ACCELERATING RESEARCH AND COLLABORATIVE CLINICAL CARE THROUGH REAL-WORLD EVIDENCE GENERATION December 7, 2024, 4:00 p.m. - 5:30 p.m. Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

#ASH24: Join myeloma specialist Dr. @szusmani.bsky.social for his presentation on "Working with Data Hub Data and Network PIs to Develop Evidence that Changes Practice in Multiple Myeloma: The COSMIC Study as Proof of Concept" today at 4pm PT at @ash-hematology.bsky.social. bit.ly/49vscmW

Join Kylee Maclachlan for the presentation "Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease." 2:15 pm PST. #ASH24 @mskcancercenter.bsky.social @szusmani.bsky.social @ash-hematology.bsky.social buff.ly/4f6J3gP

☀️ Awaken your inner poet and write your best haiku about #ASH24 or #hematology! That's 3 lines in a 5-7-5 syllable pattern. Post now through Tuesday afternoon and include #ASHaiku. You might get included in a highlights post! 🛑Remember, there's only one H in #ASHaiku! #HemeSky #Hematology

and finally, the #ASH24 #MyelomaSky **Basic/Translational Abstracts: 1019 A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome ash.confex.com/ash/2024/web...

Up next, the #ASH24 #MyelomaSky **Clinical Abstracts - RRMM @ash-hematology.bsky.social 1029 CAR-T Cell Therapy in Advanced Myeloma with EMD In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI ash.confex.com/ash/2024/web...

Alright #MyelomaSky peeps, here is my best of #ASH24 abstract list, no rank order here. I may add to this list during the meeting based on data we hear in the live meeting @ash-hematology.bsky.social

cc @rahulbanerjeemd.bsky.social @mtmdphd.bsky.social @myelomateacher.bsky.social @szusmani.bsky.social @oncoalert.bsky.social

The #ASH24 community is really ramping up in the last week before sunny San Diego. Looking forward to a phenomenal annual meeting, y'all! #ASHKudos cc @ash-hematology.bsky.social

From @szusmani.bsky.social “When entering the field do not aspire to be a ‘top influencer’… aspire to move the field forward, look up to people who have moved the field … everyone can tell fluff from substance… do the right thing for patients” So true! Or else 👇 #MyelomaSky youtu.be/qs5N8otc6bk

ASTCT recently released a special issue of Transplantation and Cellular Therapy dedicated to the latest research, challenges and innovations in chronic #GVHD management. #bmtsm www.astctjournal.org/issue/S2666-...

#ASH24 Phase I clinical trial of Anti-BCMA/GPRC5D bispecific CAR T-Cells in RRMM with Extramedullary Disease. N=6, ORR: 100% (CR: 50%) #mmsm #bmtsm ash.confex.com/ash/2024/web...

#ASH24 Phase II trial of Anito-cel in RRMM #mmsm #bmtsm N=58, ORR: 95%, CR: 62%, MRD- 10^-5: 92%, CRS: 84%, no delayed neurotoxicity #mmsm #bmtsm ash.confex.com/ash/2024/web...

#ASH24 Cilta-cel vs. SOC in RRMM (1-3 lines), CARTITUDE-4; MRD- update. N=419, median F/U: 33.6 months. >3-fold increase in MRD -ve with cilta-cel #mmsm #bmtsm ash.confex.com/ash/2024/web...

This is big news, big lesson for those who will heed the warning!

As we explore more and more HLA-specific immune based therapies, this from MSK in JAMA Onc shows that standard NGS testing can infer HLA genotypes. Other NGS providers have done/can do @adamjschoenfeld.bsky.social @mskcancercenter.bsky.social @davidaggen.bsky.social jamanetwork.com/journals/jam...

📹 Make the most of the ASH Annual Meeting — here's what you need to know before you go! www.youtube.com/watch?v=QGDX... Learn about registration hours and locations, download the #ASH24 app, & preview the virtual platform and the new food guide! 😋🍔Check your email. #HemeSky #Hematology

Don't forget, you can still access #IMS24 meeting content. If you registered for either in-person or virtual, login to the virtual platform to review all recorded sessions. virtual.imsannual.org/login

Attention #Myeloma researchers! 🌟 Don't miss out on this fantastic opportunity - apply for the IMS Translational Research Award by Jan 31, 2025! For all the details, click here: ow.ly/ge3s50TXPtt #ResearchGrant

Please join us for our Educational Workshop in Johannesburg, South Africa, from February 28 to March 1, 2025! Get ready for engaging lectures and lively roundtable discussions. Don’t miss out—register today! ➡️ bit.ly/4gnDs7X

Calling all young investigators! Are you curious about the @myeloma-society.bsky.social Career Development Award and how it can help your career? Learn more here: ow.ly/4vFx50UcLZj and apply before our January 31 deadline!

Registration is now open for the 6th Immune Effector Cell Therapies Workshop from March 28-29 in Boston. Learn more here ➡️ bit.ly/4eaHPlg

Heading out for #ASH24, I will be posting my impressions of the data on this platform and see how it goes. #mmsm #BMTsm #lymsm #leusm #CARTsm @themmrf.bsky.social @imfmyeloma.bsky.social @mskcancercenter.bsky.social @drmiguelperales.bsky.social @shematologist.bsky.social

Thanks Daniel! We will rotate this meeting between Mayo and MSK - next year in Minneapolis and save-the-date coming soon #MyelomaSky #MMsm

An interesting paper in Blood by Dr. Samur suggesting that the cell that eventually becomes myeloma first acquires extra chromosome in 2nd decade of life and becomes fully hyperdiploid by 3rd. Implication for many cancers. @pedalheadphx.bsky.social @auclairdan.bsky.social @szusmani.bsky.social

Saad Usmani, MD, shared exciting FIRST results from CEPHEUS study of a Dara quad in transplant-ineligible/transplant-deferred NDMM. Quads continue to improve outcomes & take spotlight in frontline induction. @szusmani.bsky.social #IMS24